Success Metrics

Completion Rate
0%(0/1)
Active Trials
10(91%)
Terminated
1(9%)

Phase Distribution

Ph phase_3
1
9%
Ph phase_1
3
27%
Ph phase_2
7
64%

Phase Distribution

3

Early Stage

7

Mid Stage

1

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
3(27.3%)
Phase 2Efficacy & side effects
7(63.6%)
Phase 3Large-scale testing
1(9.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

10

trials recruiting

Total Trials

11

all time

Status Distribution
Active(10)
Terminated(1)

Detailed Status

Active, not recruiting7
Recruiting3
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
10
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (27.3%)
Phase 27 (63.6%)
Phase 31 (9.1%)

Trials by Status

active_not_recruiting764%
recruiting327%
terminated19%

Recent Activity

10 active trials
Showing 5 of 11
recruitingphase_2

A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT06668961
active_not_recruitingphase_2

SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma.

NCT05022654
active_not_recruitingphase_2

SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.

NCT05020769
active_not_recruitingphase_1

A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors

NCT04603287
active_not_recruitingphase_2

SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.

NCT05020457
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT06668961Phase 2

A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Recruiting
NCT05022654Phase 2

SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma.

Active Not Recruiting
NCT05020769Phase 2

SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.

Active Not Recruiting
NCT04603287Phase 1

A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors

Active Not Recruiting
NCT05020457Phase 2

SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.

Active Not Recruiting
NCT05949606Phase 1

A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer

Recruiting
NCT05668858Phase 1

A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma

Recruiting
NCT05044897Phase 2

A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC

Active Not Recruiting
NCT05054439Phase 2

A Clinical Study of SI-B001 in Combination With Paclitaxel in the Treatment of Recurrent and Metastatic HNSCC

Active Not Recruiting
NCT05943795Phase 3

A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma

Active Not Recruiting
NCT05039944Phase 2

SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies

Terminated

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11